ACLX | tickerfilter.com

Fundamental analysis

32%

Profitability 35%

Dept financing 10%

Liquidity 50%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.13%

1 Month

-6.25%

3 Months

-0.83%

6 Months

-25.04%

1 Year

24.65%

2 Year

49.27%

Key data

Stock price

$63.71

P/E Ratio

0.00

DAY RANGE

$61.00 - $64.17

EPS

-$2.00

52 WEEK RANGE

$47.88 - $107.37

52 WEEK CHANGE

$24.65

MARKET CAP

4.147 B

YIELD

N/A

SHARES OUTSTANDING

53.756 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

2.05

PUBLIC FLOAT

AVERAGE 10 VOLUME

$327,295

AVERAGE 30 VOLUME

$737,380

Company detail

CEO: Rami Elghandour
Region: US
Website: arcellx.com
Employees: 80
IPO year: 2022

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Arcellx, Inc. engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins.

ACLX - Arcellx, Inc.